Ibopamine

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Ibopamine is a sympathomimetic drug, designed as a prodrug of epinine, used in ophthalmology.^[1] It induces mydriasis.^[2] It also has been investigated for use in the treatment of congestive heart failure.^[3]

It acts on D₁^[4]^[5] and α receptors as an agonist.^[6]

Ibopamine was first prepared by Casagrande and co-workers.^[7]

References

↑ Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). “Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability”. Arq Bras Oftalmol. 69 (5): 695–9. doi:10.1590/S0004-27492006000500015. PMID 17187138.
↑ Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). “Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure”. J Ocul Pharmacol Ther. 17 (3): 215–23. doi:10.1089/108076801750295254. PMID 11436942.
↑ van Veldhuisen DJ, Man in ‘t Veld AJ, Dunselman PH; et al. (November 1993). “Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)”. J. Am. Coll. Cardiol. 22 (6): 1564–73. doi:10.1016/0735-1097(93)90579-P. PMID 7901256.
↑ Metra M, Missale C, Spano PF, Cas LD (May 1995). “Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine”. J. Cardiovasc. Pharmacol. 25 (5): 732–40. doi:10.1097/00005344-199505000-00008. PMID 7630152.
↑ Lieverse AG, Girbes AR, Van Veldhuisen DJ; et al. (July 1995). “The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure”. Eur. Heart J. 16 (7): 937–42. PMID 7498209.
↑ “IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re…”
↑ C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). “Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites.” Arzneimittelforschung 36 291-303.

Template:Cardiac stimulants excluding cardiac glycosides Template:Mydriatics and cycloplegics

[pmid17187138-1] Magacho L, Costa ML, Dessimoni A, de Avila MP (2006). “Comparison between the 1% and 2% ibopamine provocative test in primary open-angle glaucoma patients: sensitivity, specificity and tolerability”. Arq Bras Oftalmol. 69 (5): 695–9. doi:10.1590/S0004-27492006000500015. PMID 17187138.

[pmid11436942-2] Marchini G, Babighian S, Tosi R, Perfetti S, Bonomi L (June 2001). “Effects of 2% ibopamine on pupil, refraction, anterior segment anatomy and intraocular pressure”. J Ocul Pharmacol Ther. 17 (3): 215–23. doi:10.1089/108076801750295254. PMID 11436942.

[pmid7901256-3] van Veldhuisen DJ, Man in ‘t Veld AJ, Dunselman PH; et al. (November 1993). “Double-blind placebo-controlled study of ibopamine and digoxin in patients with mild to moderate heart failure: results of the Dutch Ibopamine Multicenter Trial (DIMT)”. J. Am. Coll. Cardiol. 22 (6): 1564–73. doi:10.1016/0735-1097(93)90579-P. PMID 7901256.

[pmid7630152-4] Metra M, Missale C, Spano PF, Cas LD (May 1995). “Dopaminergic drugs in congestive heart failure: hemodynamic and neuroendocrine responses to ibopamine, dopamine, and dihydroergotoxine”. J. Cardiovasc. Pharmacol. 25 (5): 732–40. doi:10.1097/00005344-199505000-00008. PMID 7630152.

[pmid7498209-5] Lieverse AG, Girbes AR, Van Veldhuisen DJ; et al. (July 1995). “The effects of ibopamine on glomerular filtration rate and plasma norepinephrine remain preserved during prolonged treatment in patients with congestive heart failure”. Eur. Heart J. 16 (7): 937–42. PMID 7498209.

[urlIngentaConnect_Ibopamine_Stimulates_-Adrenergic_Receptors_and_D1_Dopaminergic_Re...-6] “IngentaConnect Ibopamine Stimulates -Adrenergic Receptors and D1 Dopaminergic Re…”

[7] C. Casagrande, F. Santangelo, C. Saini, F. Doggi, F. Gerli and O. Cerri (1986). “Synthesis and chemical properties of ibopamine and of related esters of N-substituted dopamines-synthesis of ibopamine metabolites.” Arzneimittelforschung 36 291-303.

[1]

[2]

[3]

[4]

[5]

[6]

[7]